CN118541364A - 氨基吡唑化合物的用途 - Google Patents
氨基吡唑化合物的用途 Download PDFInfo
- Publication number
- CN118541364A CN118541364A CN202280084861.5A CN202280084861A CN118541364A CN 118541364 A CN118541364 A CN 118541364A CN 202280084861 A CN202280084861 A CN 202280084861A CN 118541364 A CN118541364 A CN 118541364A
- Authority
- CN
- China
- Prior art keywords
- compound
- use according
- formula
- jak
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21217736 | 2021-12-24 | ||
| EP21217736.4 | 2021-12-24 | ||
| PCT/EP2022/087698 WO2023118555A1 (en) | 2021-12-24 | 2022-12-23 | Use of aminopyrazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118541364A true CN118541364A (zh) | 2024-08-23 |
Family
ID=79025165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280084861.5A Pending CN118541364A (zh) | 2021-12-24 | 2022-12-23 | 氨基吡唑化合物的用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049775A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452970A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024545293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240124925A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118541364A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022418280A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242449A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007863A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023118555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
| KR20220119024A (ko) * | 2019-12-20 | 2022-08-26 | 인터벳 인터내셔널 비.브이. | 피라졸 제약 조성물 |
-
2022
- 2022-12-23 WO PCT/EP2022/087698 patent/WO2023118555A1/en not_active Ceased
- 2022-12-23 US US18/721,916 patent/US20250049775A1/en active Pending
- 2022-12-23 JP JP2024537401A patent/JP2024545293A/ja active Pending
- 2022-12-23 CA CA3242449A patent/CA3242449A1/en active Pending
- 2022-12-23 AU AU2022418280A patent/AU2022418280A1/en active Pending
- 2022-12-23 CN CN202280084861.5A patent/CN118541364A/zh active Pending
- 2022-12-23 KR KR1020247020622A patent/KR20240124925A/ko active Pending
- 2022-12-23 MX MX2024007863A patent/MX2024007863A/es unknown
- 2022-12-23 EP EP22844123.4A patent/EP4452970A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242449A1 (en) | 2023-06-29 |
| KR20240124925A (ko) | 2024-08-19 |
| JP2024545293A (ja) | 2024-12-05 |
| US20250049775A1 (en) | 2025-02-13 |
| AU2022418280A1 (en) | 2024-06-13 |
| MX2024007863A (es) | 2024-08-30 |
| WO2023118555A1 (en) | 2023-06-29 |
| EP4452970A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10806735B2 (en) | Use of neutrophil elastase inhibitors in liver disease | |
| JP2018184440A (ja) | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 | |
| JP2025092508A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| ES2750662T3 (es) | Orvepitant para el tratamiento del prurito crónico | |
| AU2013205648A1 (en) | Combination treatment | |
| AU2024264660A1 (en) | Methods of treating behavior alterations | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20250049775A1 (en) | Use of aminopyrazole compounds | |
| US7989479B2 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
| KR101893551B1 (ko) | 치료 방법 | |
| JP2024153742A (ja) | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 | |
| KR20200136428A (ko) | 심한 변비를 치료하기 위한 조성물 및 방법 | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| CA3071804C (en) | Use of a kdm1a inhibitor in the treatment of behavior alterations | |
| HK40122445A (en) | Methods of treating behavior alterations | |
| US20200215049A1 (en) | Mast cell stabilizers for treatment of chronic inflammatory conditions | |
| WO2025264695A1 (en) | Compositions and methods for treatment | |
| JP2002501510A (ja) | ヒトにおける攪乱行動を改善し気分を高揚させる方法 | |
| JP2013018729A (ja) | アルツハイマー病治療剤の作用増強経口用剤 | |
| JP2004175786A (ja) | I型アレルギー疾患治療用組成物 | |
| CN111432813A (zh) | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 | |
| NZ625611B2 (en) | Combination treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |